S V Kirpicheva

Clinical Hospital No. 2, Yaroslavl, Russia.

3 publications 2009 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does S V Kirpicheva research?

S V Kirpicheva studies the treatment of ischemic stroke, which occurs when a blood clot blocks blood flow to the brain. They specifically investigate the drug Revelise (alteplase), looking at how it helps patients recover from strokes in practical settings, rather than just in controlled trials. Their research provides important insights into how well this treatment works for older patients and those with other medical conditions, aiming to improve recovery rates and reduce disabilities related to stroke.

Key findings

  • In a study with 2,202 patients, 49.9% had good outcomes at discharge after receiving Revelise for ischemic stroke.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%.
  • The study demonstrated that Revelise is effective in reducing stroke-related disabilities, even among older patients and those with additional health issues.

Frequently asked questions

Does Dr. Kirpicheva study ischemic stroke?
Yes, Dr. Kirpicheva specializes in researching treatments for ischemic stroke.
What treatments has Dr. Kirpicheva researched?
Dr. Kirpicheva has focused on the thrombolytic therapy with Revelise (alteplase) for treating ischemic stroke.
Is Dr. Kirpicheva's work relevant to older stroke patients?
Yes, their research specifically includes older patients and those with other health issues.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Comparative epidemiology of stroke in Kostroma and Yaroslavl].

2010

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Korneeva NN, Kirpicheva SV, Spirin NN, Pizova NV

Plain English
This study looked at the occurrence and impact of strokes in the cities of Kostroma and Yaroslavl from 2004 to 2006. They found that there were 630 strokes in Kostroma out of a population of 108,284 adults, while Yaroslavl had 542 strokes among 123,977 adults. The research highlights that understanding the causes and risk factors for strokes can lead to better prevention strategies, which is important for reducing stroke rates in these regions. Who this helps: This benefits patients at risk of stroke and healthcare providers working on prevention strategies.

PubMed

[Spontaneous subarachnoid haemorrhage].

2009

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Stepanov IO, Baranova NS, Kirpicheva SV

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.